Buspirone

Introduction Overview

Generic Name

buspirone

Brand Name

BuSpar, BuSpar Dividose, Vanspar

Dosage Form

Oral tablets/capsules

Drug Class

Miscellaneous anxiolytics, sedatives and hypnotics

Pharmacokinetics

Absorption

Buspirone is well absorbed following oral administration, with peak plasma concentrations typically reached within 60 to 90 minutes. It exhibits variable and relatively low bioavailability, approximately 4%, primarily due to extensive first-pass metabolism in the liver. Food intake does not significantly affect the overall bioavailability but may delay the time to peak concentration by approximately an hour. The absorption phase is influenced by formulation characteristics and gastrointestinal motility.

Distribution

Buspirone is widely distributed throughout the body tissues and fluids, with an apparent volume of distribution ranging between 4 and 5 liters per kilogram. It is moderately bound to plasma proteins, typically about 95%, predominantly to albumin and alpha1-acid glycoprotein. The high protein binding influences its distribution and potential drug interactions. Buspirone also crosses the blood-brain barrier, which is essential for its anxiolytic activity.

Metabolism

Buspirone undergoes extensive hepatic metabolism primarily via the cytochrome P450 3A4 (CYP3A4) isoenzyme system. The drug is transformed into several metabolites, most of which are pharmacologically inactive. One notable metabolite, 1-pyrimidinylpiperazine (1-PP), exhibits weak alpha-2 adrenergic antagonist properties, which may contribute modestly to the drug’s clinical effects and adverse events. The metabolism is subject to variability depending on CYP3A4 inhibitors or inducers, leading to potential alterations in plasma levels.

Elimination

Buspirone's elimination occurs mainly via renal excretion, with approximately 60% of the administered dose excreted in the urine as metabolites and 3–5% as unchanged drug. The rest is eliminated through feces. The elimination half-life ranges from 2 to 3 hours in healthy adults, necessitating multiple daily dosing to maintain therapeutic levels. Renal or hepatic impairment can affect the elimination kinetics, requiring dosage adjustments in these populations.

Dosage Forms

Adults

Buspirone is available as oral tablets commonly in strengths of 5 mg, 7.5 mg, 10 mg, and 15 mg. The initial recommended dose for adults with anxiety is 7.5 mg twice daily or 5 mg three times daily. Dosage can be titrated in increments of 5 mg every 2 to 3 days, with typical maintenance doses ranging from 20 to 30 mg per day, divided into two or three doses. The maximum approved dose is 60 mg per day. Dosing adjustments should be based on clinical response and tolerability.

Adolescents

Buspirone is not FDA-approved for use in individuals under 18 years of age. However, it has been used off-label in adolescents under strict medical supervision and at conservative doses, with gradual titration and careful monitoring for efficacy and side effects.

Special Populations

In patients with hepatic or renal impairment, buspirone clearance may be reduced, leading to higher plasma concentrations. Caution is advised, and dose adjustments or extended dosing intervals may be required. Elderly patients may have increased sensitivity to buspirone's effects; starting at lower doses is recommended. Pregnant or breastfeeding women should use buspirone only when clearly needed, as adequate safety data are limited.

Mechanism Of Action

Buspirone is a non-benzodiazepine anxiolytic that exerts its effects primarily through partial agonist activity at the serotonin 5-HT1A receptors situated in both presynaptic and postsynaptic locations within the central nervous system. By stimulating the presynaptic 5-HT1A autoreceptors, buspirone decreases serotonin neuronal firing rate, leading to modulated serotonin release and neurotransmission, which contributes to anxiolytic effects. Furthermore, its partial agonism at postsynaptic 5-HT1A receptors in limbic and cortical brain regions enhances inhibitory neurotransmission involved in anxiety regulation.

Unlike benzodiazepines, buspirone does not bind to GABA-A receptors and thus lacks sedative, muscle relaxant, or anticonvulsant properties. Additionally, buspirone has negligible affinity for dopamine D2 receptors, differentiating it from antipsychotic agents. It also exerts moderate antagonism on presynaptic dopamine D2 autoreceptors, contributing to dopaminergic modulation, which may influence mood and cognitive functions.

Buspirone's metabolite, 1-pyrimidinylpiperazine, exhibits weak antagonism at alpha-2 adrenergic receptors, which may influence noradrenergic tone and contribute to clinical effects such as mild stimulation or nervousness in some patients. Overall, buspirone produces anxiolytic effects without central nervous system depression, minimizing risks of dependency, withdrawal, and sedation common with other anxiolytics.

Clinical studies demonstrate that buspirone's anxiolytic efficacy emerges gradually over 2 to 4 weeks, reflecting neuroadaptive changes in serotonergic receptor sensitivity and downstream signaling pathways. Its unique mechanism provides benefit in generalized anxiety disorder, particularly in patients who require anxiolysis without sedation or cognitive impairment.

Pharmacological Actions

Partial agonist at central serotonin 5-HT1A receptors
Modulation of serotonergic neurotransmission leading to anxiolytic effects
Weak antagonism at presynaptic dopamine D2 autoreceptors
Non-sedative anxiolytic without muscle relaxant or anticonvulsant properties
Minimal affinity for benzodiazepine receptors and no GABAergic activity
Mild antagonism of alpha-2 adrenergic receptors via active metabolite
Reduction of anxiety symptoms without causing dependence or significant CNS depression
Improvement of physical symptoms associated with anxiety such as dizziness and palpitations
Neuroadaptive effects leading to delayed onset of anxiolytic action
Modulation of limbic system activity which regulates emotional responses

Therapeutic Clinical Uses

Treatment of generalized anxiety disorder (GAD)
Management of anxiety symptoms such as tension, fear, irritability, and pounding heartbeat
Alternative anxiolytic in patients intolerant or resistant to benzodiazepines
Useful in patients with history of substance abuse where non-sedating anxiolytics are preferred
Adjunctive therapy for anxiety symptoms in various psychiatric disorders
Treatment of anxiety symptoms in elderly patients due to favorable safety profile
Potential off-label use for anxiety in adolescents under close supervision
Relief of physical manifestations of anxiety including dizziness and fatigue
Long-term management of chronic anxiety where daily dosing is feasible

Side Or Adverse Effects

Common headache
Dizziness and lightheadedness
Drowsiness or fatigue
Insomnia or sleep disturbances
Nausea and gastrointestinal upset
Feeling nervous or excitement (paradoxical reactions)
Chest pain (rare and warrants immediate medical evaluation)
Shortness of breath
Rare allergic reactions including swelling, hives, or difficulty breathing
Possible orthostatic hypotension leading to falls, especially in elderly
Less commonly, dry mouth
Rare reports of palpitations
Possible irritability or restlessness
No significant risk of dependence or withdrawal symptoms
Rare extrapyramidal symptoms reported

Precautions

Avoid use in combination with MAO inhibitors within 14 days due to risk of hypertensive crisis or serotonin syndrome
Use caution in patients with hepatic or renal impairment due to altered drug clearance
Monitor elderly patients closely for increased sensitivity and risk of dizziness
Inform patients about potential impairment of ability to perform tasks requiring alertness
Avoid abrupt discontinuation to prevent return or worsening of anxiety symptoms
Use cautiously in pregnant or breastfeeding women considering limited data
Monitor for potential drug interactions especially with CYP3A4 inhibitors or inducers
Ensure gradual dose titration to minimize side effects
Inform patients about potential false positive drug screening results with buspirone use
Advise patients to avoid grapefruit juice as it may increase buspirone levels
Use cautiously with other CNS depressants to avoid additive effects
Consider lower starting doses in medically compromised patients
Monitor blood pressure due to rare orthostatic hypotension

Warnings

Do not use buspirone if an MAO inhibitor has been taken within the past 14 days
Risk of serotonin syndrome when combined with serotonergic drugs including SSRIs and triptans
Not approved for treatment of psychotic disorders or acute anxiety episodes requiring rapid relief
Potential for false positive urine drug screening with buspirone use
Use with caution in patients with pre-existing cardiovascular disease due to rare reports of chest pain
Buspirone may impair thinking or reactions - caution when driving or operating machinery
Avoid alcohol consumption while on buspirone to reduce sedation and CNS effects
Report allergic reactions promptly including rash, swelling or breathing difficulties
Dose adjustment or close monitoring recommended in hepatic and renal impairment
Use cautiously in elderly due to fall risk from dizziness or somnolence
Pregnancy category B; use only if benefits outweigh risks
Gradual dose titration recommended to minimize adverse effects

Contraindications

Known hypersensitivity or allergy to buspirone or any formulation component
Use of monoamine oxidase inhibitors (MAOIs) within the prior 14 days
Concomitant use with linezolid, methylene blue injection, or other irreversible MAOIs
Hypersensitivity to any ingredients in branded or generic formulations
Use in patients with severe hepatic or renal impairment requiring avoidance or dose adjustment
Do not use as monotherapy for psychotic disorders or acute panic attacks

Drug Interactions

Concomitant use with MAO inhibitors can cause hypertensive crisis or serotonin syndrome
CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) increase buspirone plasma levels, enhancing adverse effects
CYP3A4 inducers (e.g., rifampin, carbamazepine) reduce buspirone efficacy by increasing its metabolism
Additive CNS depressant effects when used with benzodiazepines, alcohol, opioids, or other sedatives
Possible drug screening interference leading to false positive results
Use with serotonergic drugs (SSRIs, SNRIs, triptans) increases risk of serotonin syndrome
Grapefruit juice can inhibit CYP3A4, increasing buspirone levels and side effects
Co-administration with antiepileptic drugs may alter drug levels
Interactions with blood pressure medications may occur due to additive hypotensive effects
St. John's Wort may reduce buspirone effectiveness by inducing metabolism
Potential interaction with antidepressants like trazodone increasing sedation risk
Avoid abrupt discontinuation of benzodiazepines when switching to buspirone to prevent withdrawal

Preparations Of The Drug

Buspirone oral tablets available in strengths of 5 mg, 7.5 mg, 10 mg, and 15 mg
Extended-release formulations available under brand names such as BuSpar Dividose
Generic immediate-release oral tablets and capsules
Bulk powder formulations for compounding (less common)
Available in scored tablets allowing splitting for dose adjustment
Commercially available as prescription only formulations
Some preparations have flavoring agents to improve palatability
Packaged in blister packs or bottles depending on manufacturer
Formulations free from common allergens like gluten or lactose may be available